SCHEMBL22803116

CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)NCCOCCNC(=O)CCCC[C@@H]2SC[C@@H]3NC(=O)N[C@@H]32)C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC1=O

nearest known ligand 0.63

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	MAFG	O15525	1/20	0.63

▸	KRAS	P01116	6/20	0.50

▸	BCL2A1	Q16548	4/20	0.47

▸	MCL1	Q07820	3/20	0.47

▸	HSP90AB1	P08238	1/20	0.47

▸	NFE2L2	Q16236	1/20	0.46

▸	ESR1	P03372	3/20	0.44

▸	ESR2	Q92731	3/20	0.44

▸	EED	O75530	1/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL24918853	0.84	BCL2A1 (0.50)	MAFGKRASBCL2A1MCL1HSP90AB1
SCHEMBL20694605	0.82	ESR1 (0.52)	MAFGKRASBCL2A1MCL1HSP90AB1
SCHEMBL22803251	0.81	BCL2A1 (0.51)	MAFGKRASBCL2A1MCL1HSP90AB1
SCHEMBL24918858	0.79	KRAS (0.52)	MAFGKRASBCL2A1MCL1HSP90AB1
SCHEMBL29343923	0.75	MCL1 (0.45)	KRASBCL2A1MCL1HSP90AB1NFE2L2
SCHEMBL24919299	0.74	KRAS (0.47)	MAFGKRASBCL2A1MCL1HSP90AB1
SCHEMBL20694360	0.73	ESR1 (0.49)	MAFGKRASBCL2A1MCL1NFE2L2
SCHEMBL20694606	0.73	ESR1 (0.51)	MAFGKRASBCL2A1MCL1NFE2L2
SCHEMBL20694567	0.72	ESR1 (0.53)	MAFGBCL2A1MCL1NFE2L2ESR1
SCHEMBL24918851	0.72	CTNNB1 (0.49)	MAFGKRASBCL2A1MCL1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20200390895-A1	UNIVERSAL ABT COMPOUNDS AND USES THEREOF	KLEO PHARMACEUTICALS, INC.	2020-12-17	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20200390895-A1	UNIVERSAL ABT COMPOUNDS AND USES THEREOF	CD47, MCL1, BCL9	MAFG 3473/4885KRAS 70/4885BCL2A1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.